CellPoint Digital Secures $25 Million Investment to Boost Global Expansion and Entry Into New Markets
5.1.2022 11:11:00 EET | Business Wire | Press release
CellPoint Digital, a leading global provider of digital commerce and payment solutions, today announced an equity financing round of $25M provided by Toscafund and its private equity arm, Penta Capital, to build on a series of major successes in recent years.
The move follows a series of investments by Toscafund and Penta Capital into CellPoint Digital following their initial investment in 2019 and brings their total investment to over $56M. It also marks a strengthening of the relationship between the businesses. As a market leader in payment orchestration for travel, CellPoint Digital is now offering its platform to new markets including retail, gaming, crypto and digital content.
By orchestrating payments across regions and payment methods, CellPoint Digital allows merchants to adopt a multi-acquirer payments model that opens up new opportunities for growth. CellPoint Digital helps increase top-line revenue utilizing intelligent routing, increasing authorizations, and providing system uptime transparency, and reduces the operation cost of accepting cross border payments. CellPoint Digital also adds value at checkout by delivering a frictionless payment experience, presenting customers with the payment methods they want to use, no matter where they are in the world.
Kristian Gjerding, CEO at CellPoint Digital said: “The past few years have seen extraordinary growth for CellPoint Digital. We continue to experience strong demand from a range of enterprises wishing to optimise their digital payment and commerce solutions, while countering the major challenges they face with existing providers to deliver quickly and cost-efficiently.”
“With a business foundation that is stronger than it’s ever been, the logical next step is to widen our global reach and penetrate new market verticals that stand to be transformed by our solutions.”
Steven Scott, Founding Partner of Penta Capital, said: “We are delighted to finance this next stage of CellPoint Digital’s expansion. The company continues to solve the most critical problem that businesses face today: the optimization of a customer’s entire path to purchase across all their digital channels.”
“Based on winning key new clients, and with the aggressive growth strategy and penetration into new sectors, we see yet another compelling growth opportunity and look forward to working together with CellPoint Digital’s experienced management team to support this new phase of development.”
Echoing the thoughts of Penta Capital, Paul Glover, CFO at CellPoint Digital: “Our expansion plan is exciting, and we are thrilled to partner with Penta Capital once again to further accelerate our company’s development.”
“Toscafund have a great track record of investing in high-growth companies and their commitment is testament to our market traction and growth potential by delivering high ROI digital solutions. The new investment will enable us to further scale our team globally as well as drive additional innovation into our unique platform.”
Ends
About CellPoint Digital
CellPoint Digital is a fintech leader in payment orchestration. CellPoint Digital’s main solution is a powerful omni-channel Payment Orchestration Platform that optimises digital payment transactions, from cards or alternative payment methods, and accelerates the deployment of new payment options. Merchants can easily scale their own payment ecosystem across the world, unify the customer payment experience across their website, mobile apps and other channels, optimize the routing of each transaction, increase conversion rates and minimise payment costs.
CellPoint Digital has offices in Copenhagen, Dallas, Dubai, London, Miami, Pune and Singapore. Visit www.cellpointdigital.com to learn more.
About Toscafund Asset Management LLP
Toscafund Asset Management LLP, founded in 2000 by Martin Hughes, is a specialist investment manager with approximately $4.5bn of assets under management. Specialist areas of investment include listed equities in the financials and payments sectors, growth capital for private companies, UK commercial property and bespoke private equity deals. Toscafund is based in London with offices also in Manchester (UK), Melbourne, New York and Hong Kong.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220105005122/en/
Contact information
Becky Sales
becky@skyparlour.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
TIME Names Xenco Medical one of the TIME100 Most Influential Companies in the World and the Winner of the 2026 TIME100 Impact Award in Health1.5.2026 13:07:00 EEST | Press release
Time Magazine has named pioneering medical technology company Xenco Medical as one of the TIME100 Most Influential Companies in the World and the Winner of the 2026 TIME100 Impact Award in Health. Widely regarded as the most prestigious recognition in business and technology, being selected to the TIME100 List remains the most coveted accolade that a company can achieve globally. The TIME100 Impact Awards are given to only 5 recipients each year, making it the rarest of honors that a company can receive and a profound recognition of transformative, global impact. Xenco Medical was honored by Time as the sole recipient of the TIME100 Impact Award in Health in 2026, signifying its leading, global distinction in impact on healthcare. According to Time Magazine, the TIME100 Most Influential Companies list highlights “companies making an extraordinary impact around the world.” The honor bestowed by Time comes after Xenco Medical was named the 2025 Medical Device/ Diagnostics Company of the
Inspirit Capital Completes Acquisition of Kaplan Languages Group1.5.2026 02:17:00 EEST | Press release
Inspirit Capital, a specialist investor in corporate carve-outs, and Kaplan, the global education company, have announced the completion of Inspirit’s acquisition of Kaplan Languages Group (KLG) from Kaplan. Financial terms are not being disclosed. KLG, a leading global language education platform, comprises Kaplan International Languages, Alpadia Language Schools, Azurlingua, and ESL Education. Inspirit Capital will support KLG in delivering on its ambitious growth plans, whilst continuing its fundamental mission to transform lives through language education. The next phase of ownership will see the development and launch of a refreshed standalone brand identity for KLG, with further announcements to follow on this in due course. KLG will continue to use the Kaplan name under a transitional license from Kaplan, Inc. until a new brand is announced. About Kaplan Languages Group Since 2006, KLG has provided the highest quality language education and cultural immersion experiences. Kaplan
Grindr Nominates Three New Directors to Its Board of Directors1.5.2026 00:16:00 EEST | Press release
Grindr Inc. (NYSE: GRND), the Global Gayborhood in Your Pocket™, today announced the nomination of Rob Solomon, Lisa Gersh, and Fadi Hanna to stand for election to its Board of Directors at the Annual Meeting of Shareholders on June 2, 2026. Rob Solomon is a deeply seasoned technology CEO and operator in consumer internet and marketplaces. He has held CEO and COO roles at scaled platforms including GoFundMe, Groupon, and Kayak-predecessor SideStep, and is currently CEO of leading electric aviation company H55. Lisa Gersh is a CEO and long-tenured public company director with deep experience across consumer brands, media, and commerce. She has served on the Hasbro (NASDAQ: HAS) board since 2010 and has led businesses including Oxygen Media, GOOP, and Alexander Wang. Fadi Hanna is Chief Risk Officer at Bloomberg L.P., overseeing enterprise risk across the organization. He previously worked at J.P. Morgan and has served on the board of Immigration Equality. “Over the last few years, we bu
The Empire State Building Celebrates 95 Years as the ‘World’s Most Famous Building’30.4.2026 23:42:00 EEST | Press release
The Empire State Building (ESB), the “World’s Most Famous Building,” will celebrate its 95th anniversary on May 1, 2026, with new offers at the Empire State Building Observation Deck, a special birthday tower lighting display, and a slate of celebrations to honor its legacy and future. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430693323/en/ The Empire State Building Celebrates 95 Years as the ‘World’s Most Famous Building’ “The Empire State Building celebrates its 95th anniversary, still the ‘World’s Most Famous Building,’ a modernized, sustainability leader as technologically advanced today as the day she was completed, and the winner of #1 Top Attraction in the United States in Tripadvisor’s Travelers’ Choice Awards for 2026,” said Anthony E. Malkin, chairman and CEO of Empire State Realty Trust. Anniversary Offerings and Experiences To mark its 95th anniversary, the Empire State Building will debut new experiences
MRM Health’s Lead Candidate MH002 Granted Fast Track Designation by U.S. FDA for the Treatment of Mild-to-Moderate Ulcerative Colitis30.4.2026 23:17:00 EEST | Press release
MRM Health, a clinical-stage biopharmaceutical company developing therapeutics for immune-mediated diseases, which unlock the power of the microbiome to restore immune balance, today announced that MH002, the Company’s lead rationally designed Live Biotherapeutic Product (LBP) candidate, has been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of mild-to-moderate ulcerative colitis (UC). MH002 today is the most advanced LBP targeting inflammatory bowel disease (IBD)-specific mechanisms and is composed of a rationally designed microbial consortium of six well-characterized commensal strains. The FDA’s Fast Track is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need. The purpose is to get important drugs to patients earlier. Fast Track designation enables frequent communication with the FDA to discuss the drug's development plan and ensure collection o
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom